TABLE 4.
Unadjusted Factors Associated with Overall Survival in EGC and AGC
| RFS | OS | |||||
| Variable | HR | 95% CI | P | HR | 95% CI | P |
| EGC | ||||||
| WHO histology and grade | ||||||
| PD (vs WMD) | 0.82 | 0.53 to 1.26 | 0.357 | 0.73 | 0.54 to 0.98 | 0.036 |
| SRC (vs WMD) | 0.26 | 0.14 to 0.49 | <0.001 | 0.30 | 0.20 to 0.45 | <0.001 |
| SRC (vs non-SRC) | 0.28 | 0.15 to 0.52 | <0.001 | 0.33 | 0.22 to 0.48 | <0.001 |
| Age at diagnosis | 1.03 | 1.01 to 1.04 | 0.002 | 1.09 | 1.07 to 1.10 | <0.001 |
| Female sex | 0.55 | 0.36 to 0.84 | 0.005 | 0.45 | 0.34 to 0.61 | <0.001 |
| AJCC stage II (vs stage I) | 7.22 | 4.59 to 11.37 | <0.001 | 3.08 | 2.03 to 4.69 | <0.001 |
| Submucosal invasion | 2.02 | 1.40 to 2.92 | <0.001 | 1.65 | 1.30 to 2.09 | <0.001 |
| Lymph node metastasis | 6.15 | 4.27 to 8.88 | <0.001 | 2.43 | 1.80 to 3.28 | <0.001 |
| Location* | ||||||
| Middle (vs upper) | 1.60 | 0.67 to 3.80 | 0.289 | 0.99 | 0.64 to 1.53 | 0.952 |
| Lower (vs upper) | 2.10 | 0.92 to 4.81 | 0.080 | 0.93 | 0.61 to 1.42 | 0.735 |
| AGC | ||||||
| WHO histology and grade | ||||||
| PD (vs WMD) | 1.40 | 1.23 to 1.60 | <0.001 | 1.31 | 1.16 to 1.49 | <0.001 |
| SRC (vs WMD) | 1.42 | 1.19 to 1.69 | <0.001 | 1.36 | 1.15 to 1.60 | <0.001 |
| SRC (vs non-SRC) | 1.15 | 0.99 to 1.34 | 0.066 | 1.15 | 1.00 to 1.33 | 0.050 |
| Age at diagnosis | 1.00 | 1.00 to 1.01 | 0.650 | 1.02 | 1.02 to 1.03 | <0.001 |
| Female sex | 1.13 | 1.00 to 1.27 | 0.051 | 1.05 | 0.93 to 1.17 | 0.452 |
| AJCC stage | ||||||
| Stage II (vs stage I) | 3.72 | 2.50 to 5.53 | <0.001 | 2.14 | 1.61 to 2.83 | <0.001 |
| Stage III (vs stage I) | 14.20 | 9.75 to 20.68 | <0.001 | 7.02 | 5.42 to 9.09 | <0.001 |
| Tumor stage | ||||||
| T3 (vs T2) | 2.28 | 1.80 to 2.89 | <0.001 | 1.90 | 1.55 to 2.33 | <0.001 |
| T4 (vs T2) | 5.75 | 4.68 to 7.06 | <0.001 | 4.24 | 3.57 to 5.05 | <0.001 |
| Node stage | ||||||
| N1 (vs N0) | 2.29 | 1.82 to 2.90 | <0.001 | 1.69 | 1.38 to 2.07 | <0.001 |
| N2 (vs N0) | 3.91 | 3.16 to 4.84 | <0.001 | 2.64 | 2.19 to 3.18 | <0.001 |
| N3 (vs N0) | 8.82 | 7.29 to 10.67 | <0.001 | 6.31 | 5.39 to 7.40 | <0.001 |
| Location | ||||||
| Middle (vs upper) | 0.96 | 0.81 to 1.15 | 0.684 | 0.97 | 0.82 to 1.14 | 0.683 |
| Lower (vs upper) | 1.05 | 0.89 to 1.24 | 0.566 | 1.05 | 0.90 to 1.23 | 0.532 |
| Whole (vs upper) | 2.98 | 1.53 to 5.83 | 0.001 | 5.35 | 3.11 to 9.20 | <0.001 |
AGC indicates advanced gastric cancer; CI, confidence interval, EGC, early gastric cancer; HR, hazard ratio; PD, poorly differentiated; SRC, signet ring cell carcinoma; WMD, well-to-moderately differentiated.
*Only two EGC patients had ‘whole stomach’ cancers and were therefore excluded from analysis.